United States of America – October 23, 2025 – The Insight Partners has released its latest report, “Stomach Cancer Market : Segmentation, Growth, and Leading Companies,” which provides an in-depth overview of the therapeutic landscape, market trends, and future growth opportunities in the global stomach cancer treatment industry through 2030.

Overview of Stomach Cancer Market

The stomach cancer market size is projected to grow from US$ 3,575.04 million in 2022 to US$ 10,751.42 million by 2030, at an estimated CAGR of 14.8% during 2022–2030. This rapid expansion is fueled by the growing global incidence of gastric malignancies, increasing adoption of immunotherapies, and strong advancements in biomarker-driven and targeted drug development for improved patient outcomes.

Asia-Pacific currently leads the global market, owing to higher disease prevalence, improving access to oncological care, and rising healthcare investment, while North America and Europe continue to drive innovation in targeted and biologic therapeutic modalities.

Get Sample PDF:- https://www.theinsightpartners.com/sample/TIPRE00004053

Segments Covered

• By Type

  • Adenocarcinomas

  • Gastrointestinal Stromal Tumors

  • Neuroendocrine Tumors

  • Lymphoma

• By Treatment

  • Targeted and Immunotherapy Drugs

  • Chemotherapy and Combination Drugs

• By Route of Administration

  • Oral

  • Parenteral

• By Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

Spotting Emerging Trends

• Technological Advancements: Immunotherapies such as PD-1/PD-L1 inhibitors (nivolumab and pembrolizumab) and HER2-targeting monoclonal antibodies are revolutionizing first-line treatment for advanced gastric cancers, improving survival outcomes globally.

• Changing Clinical Practices: Increased adoption of companion diagnostics and personalized oncology has strengthened the patient-treatment match rates, optimizing therapeutic response and minimizing adverse events.

• R&D Investments: Global pharmaceutical companies are focusing on combination therapies and drug repurposing for metastatic stomach cancer management, resulting in a dynamic clinical pipeline and accelerated regulatory approvals.

Growth Opportunities

The Asia-Pacific region is expected to maintain its strong growth trajectory through 2030, driven by high patient volumes and expanding healthcare infrastructure. North America remains a technology leader in drug discovery and clinical trials, while developing regions are emerging as new hotspots for cost-effective biologics manufacturing.

Market Leaders and Key Company Profiles

• Bristol Myers Squibb Company

• Novartis AG

• Merck & Co., Inc.

• Eli Lilly and Company

• Biocon

• Teva Pharmaceutical Industries Ltd.

• Celltrion Healthcare Co., Ltd.

• Samsung Bioepis

• Pfizer Inc.

Conclusion

The Stomach Cancer Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022–2030 underscores a robust evolution in gastric oncology, marked by transformative biologics, rising clinical collaborations, and breakthroughs in molecular diagnostics. The market outlook remains strong, supported by expanding therapeutic access, ongoing R&D, and the integration of precision treatments across developed and emerging healthcare ecosystems.

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us:

If you have any queries about this report or if you would like further information, please get in touch with us:
Contact Person: Ankit Mathur
E-mail: [email protected]
Phone: +1-646-491-9876
Also Available in : 日本 | 한국어 | Français | لعربية< | 中文 | Italiano | Español | Deutsch